Aumolertinib

Last updated on: 20.11.2026

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

Definition This section has been translated automatically.

Aumolertinib is an irreversible inhibitor of EGFR tyrosine kinase.

The active ingredient is intended for the treatment of non-small cell lung cancer (NSCLC).

The active ingredient targets specific activating EGFR mutations, including exon 19 deletions (Ex19Del) and the L858R mutation, as well as the T790M resistance mutation. 

Positive recommendation by the EMA in November 2026.

Last updated on: 20.11.2026